Metabolic Surgery May Be Beneficial in MASH-Related Cirrhosis, Obesity
By Elana Gotkine HealthDay Reporter
MONDAY, Feb. 3, 2025 -- For patients with compensated metabolic dysfunction-associated steatohepatitis (MASH)-related cirrhosis and obesity, metabolic surgery is associated with a lower risk for incident major adverse liver outcomes (MALO), according to a study published online Jan. 27 in Nature Medicine.
Ali Aminian, M.D., from the Bariatric and Metabolic Institute at the Cleveland Clinic, and colleagues conducted an observational study to compare the effects of metabolic surgery and nonsurgical treatment in patients with obesity and compensated histologically proven MASH-related cirrhosis. The time-to-incident MALO was compared for 62 patients who underwent metabolic surgery and 106 nonsurgical controls who were followed for a mean of 10.0 ± 4.5 years.
The researchers found that the 15-year cumulative incidence of MALO was 20.9 and 46.4 percent in the surgical and nonsurgical groups, respectively, with an adjusted hazard ratio of 0.28. The 15-year cumulative incidence of decompensated cirrhosis was 15.6 and 30.7 percent in the surgical and nonsurgical groups, respectively (adjusted hazard ratio, 0.20).
"In the absence of approved medical therapies for compensated MASH-related cirrhosis, metabolic surgery may represent a safe and effective therapeutic option to influence the trajectory of cirrhosis in selected patients," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Minor Complications Up for Black Patients After Weight-Loss Surgery
MONDAY, June 23, 2025 -- Black patients have a higher incidence of minor complications after metabolic and bariatric surgery, according to a study presented at the annual meeting...
ADA: Ecnoglutide Yields Superior, Sustained Reduction in Body Weight
MONDAY, June 23, 2025 -- For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon like peptide 1 receptor agonist...
Dementia Caregivers Have Modifiable Risk Factors Increasing Their Own Risk
FRIDAY, June 20, 2025 -- Six in 10 dementia caregivers report having at least one modifiable risk factor that could increase their own chances of developing dementia, according to...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.